EA202191292A1 - METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY - Google Patents

METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY

Info

Publication number
EA202191292A1
EA202191292A1 EA202191292A EA202191292A EA202191292A1 EA 202191292 A1 EA202191292 A1 EA 202191292A1 EA 202191292 A EA202191292 A EA 202191292A EA 202191292 A EA202191292 A EA 202191292A EA 202191292 A1 EA202191292 A1 EA 202191292A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
cancer immunotherapy
immunotherapy
cancer
Prior art date
Application number
EA202191292A
Other languages
Russian (ru)
Inventor
Томас Ларс Андресен
Дуглас Джоунс
Елена Геретти
Гульзар Ахмад
Original Assignee
Торк Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Торк Терапьютикс, Инк. filed Critical Торк Терапьютикс, Инк.
Priority claimed from PCT/US2019/061837 external-priority patent/WO2020102745A1/en
Publication of EA202191292A1 publication Critical patent/EA202191292A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Описаны композиции и способы для иммунотерапии рака и, более конкретно, иммунные клетки, нагруженные белковыми кластерами и/или иммуностимулирующими слитыми молекулами (IFM), в комбинации с ингибитором ингибитора контрольных точек.Described are compositions and methods for immunotherapy of cancer and, more specifically, immune cells loaded with protein clusters and / or immunostimulatory fusion molecules (IFMs) in combination with a checkpoint inhibitor inhibitor.

EA202191292A 2019-11-04 2019-11-15 METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY EA202191292A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930399P 2019-11-04 2019-11-04
PCT/US2019/061837 WO2020102745A1 (en) 2018-11-15 2019-11-15 Methods and compositions for cancer immunotherapy

Publications (1)

Publication Number Publication Date
EA202191292A1 true EA202191292A1 (en) 2021-08-12

Family

ID=77515185

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191292A EA202191292A1 (en) 2019-11-04 2019-11-15 METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY

Country Status (1)

Country Link
EA (1) EA202191292A1 (en)

Similar Documents

Publication Publication Date Title
CO2018011668A2 (en) Neoantigens and methods of their use
EA202092945A1 (en) DIFFERENT ANTIGEN BINDING DOMAINS, NEW PLATFORMS AND OTHER IMPROVEMENTS FOR CELL THERAPY
CY1125392T1 (en) COMPOSITIONS AND METHODS OF PROTEINS
MX2017005344A (en) Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy.
EA201991168A1 (en) PROTEIN BINDING PROSTATIC SPECIFIC MEMBRANE ANTIGEN
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
WO2018187356A3 (en) Protein antigens and uses thereof
DOP2019000011A (en) BISPECIFIC ANTIBODY TYPE UNION PROTEINS THAT SPECIFICALLY JOIN CD3 AND CD123
EA202091887A1 (en) COMBINED CANCER THERAPY USING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
MX2020009116A (en) Trispecific antigen binding proteins.
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
MX2021005564A (en) Methods and compositions for cancer immunotherapy.
EA202191257A1 (en) ANTI-CANCER THERAPY BASED ON IMMUNOCYTES BINDING LIV1
MX2023014077A (en) Anti-vegf protein compositions and methods for producing the same.
EA201791918A1 (en) MODIFICATION OF PROTEINS OF CELL-OWNERS
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2022001947A (en) Antibodies that bind to lrp5 proteins and methods of use.
AU2018276376A1 (en) Cell culture methods
BR112019007365A2 (en) methods and compositions for tusc2 immunotherapy
CR20220061A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
EA202191292A1 (en) METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
MX2021011609A (en) Modulators of cell surface protein interactions and methods and compositions related to same.
EA201992875A1 (en) T-CELLS WITH REDUCED SURFACE FUCHOSILING AND METHODS FOR PRODUCING AND USING THEM
BR112019004017A2 (en) chimeric proteins to direct dsrna
WO2023052842A9 (en) Survivin and mage-a9 dual-targeted immunotherapy